Report Detail
Global Herpes Labialis Drugs Market Insights, Forecast to 2025
- RnM3241689 |
- 02 April, 2019 |
- Global |
- 123 Pages |
- QYResearch |
- Pharma & Healthcare
The global Herpes Labialis Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Herpes Labialis Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Herpes Labialis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Herpes Labialis Drugs in these regions.
This research report categorizes the global Herpes Labialis Drugs market by top players/brands, region, type and end user. This report also studies the global Herpes Labialis Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher
Market size by Product
Valacyclovir
Aciclovir
Famciclovir
Docosanol
Other
Market size by End User
External Use
Oral
Injection
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Herpes Labialis Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Herpes Labialis Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Herpes Labialis Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Herpes Labialis Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Herpes Labialis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Herpes Labialis Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Herpes Labialis Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Herpes Labialis Drugs Market Size Growth Rate by Product
- 1.4.2 Valacyclovir
- 1.4.3 Aciclovir
- 1.4.4 Famciclovir
- 1.4.5 Docosanol
- 1.4.6 Other
- 1.5 Market by End User
- 1.5.1 Global Herpes Labialis Drugs Market Size Growth Rate by End User
- 1.5.2 External Use
- 1.5.3 Oral
- 1.5.4 Injection
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Herpes Labialis Drugs Market Size
- 2.1.1 Global Herpes Labialis Drugs Revenue 2014-2025
- 2.1.2 Global Herpes Labialis Drugs Sales 2014-2025
- 2.2 Herpes Labialis Drugs Growth Rate by Regions
- 2.2.1 Global Herpes Labialis Drugs Sales by Regions
- 2.2.2 Global Herpes Labialis Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Herpes Labialis Drugs Sales by Manufacturers
- 3.1.1 Herpes Labialis Drugs Sales by Manufacturers
- 3.1.2 Herpes Labialis Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Herpes Labialis Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Herpes Labialis Drugs Revenue by Manufacturers
- 3.2.1 Herpes Labialis Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Herpes Labialis Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Herpes Labialis Drugs Price by Manufacturers
- 3.4 Herpes Labialis Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Herpes Labialis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Herpes Labialis Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Herpes Labialis Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Herpes Labialis Drugs Sales by Product
- 4.2 Global Herpes Labialis Drugs Revenue by Product
- 4.3 Herpes Labialis Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Herpes Labialis Drugs Breakdown Data by End User
6 North America
- 6.1 North America Herpes Labialis Drugs by Countries
- 6.1.1 North America Herpes Labialis Drugs Sales by Countries
- 6.1.2 North America Herpes Labialis Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Herpes Labialis Drugs by Product
- 6.3 North America Herpes Labialis Drugs by End User
7 Europe
- 7.1 Europe Herpes Labialis Drugs by Countries
- 7.1.1 Europe Herpes Labialis Drugs Sales by Countries
- 7.1.2 Europe Herpes Labialis Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Herpes Labialis Drugs by Product
- 7.3 Europe Herpes Labialis Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Herpes Labialis Drugs by Countries
- 8.1.1 Asia Pacific Herpes Labialis Drugs Sales by Countries
- 8.1.2 Asia Pacific Herpes Labialis Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Herpes Labialis Drugs by Product
- 8.3 Asia Pacific Herpes Labialis Drugs by End User
9 Central & South America
- 9.1 Central & South America Herpes Labialis Drugs by Countries
- 9.1.1 Central & South America Herpes Labialis Drugs Sales by Countries
- 9.1.2 Central & South America Herpes Labialis Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Herpes Labialis Drugs by Product
- 9.3 Central & South America Herpes Labialis Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Herpes Labialis Drugs by Countries
- 10.1.1 Middle East and Africa Herpes Labialis Drugs Sales by Countries
- 10.1.2 Middle East and Africa Herpes Labialis Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Herpes Labialis Drugs by Product
- 10.3 Middle East and Africa Herpes Labialis Drugs by End User
11 Company Profiles
- 11.1 GSK
- 11.1.1 GSK Company Details
- 11.1.2 Company Business Overview
- 11.1.3 GSK Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 GSK Herpes Labialis Drugs Products Offered
- 11.1.5 GSK Recent Development
- 11.2 Novartis
- 11.2.1 Novartis Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Novartis Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Novartis Herpes Labialis Drugs Products Offered
- 11.2.5 Novartis Recent Development
- 11.3 Teva
- 11.3.1 Teva Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Teva Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Teva Herpes Labialis Drugs Products Offered
- 11.3.5 Teva Recent Development
- 11.4 Mylan
- 11.4.1 Mylan Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Mylan Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Mylan Herpes Labialis Drugs Products Offered
- 11.4.5 Mylan Recent Development
- 11.5 Cadila
- 11.5.1 Cadila Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Cadila Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Cadila Herpes Labialis Drugs Products Offered
- 11.5.5 Cadila Recent Development
- 11.6 Apotex
- 11.6.1 Apotex Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Apotex Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Apotex Herpes Labialis Drugs Products Offered
- 11.6.5 Apotex Recent Development
- 11.7 Daewoong Pharmaceutical
- 11.7.1 Daewoong Pharmaceutical Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Daewoong Pharmaceutical Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Daewoong Pharmaceutical Herpes Labialis Drugs Products Offered
- 11.7.5 Daewoong Pharmaceutical Recent Development
- 11.8 Livzon
- 11.8.1 Livzon Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Livzon Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Livzon Herpes Labialis Drugs Products Offered
- 11.8.5 Livzon Recent Development
- 11.9 Luoxin
- 11.9.1 Luoxin Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Luoxin Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Luoxin Herpes Labialis Drugs Products Offered
- 11.9.5 Luoxin Recent Development
- 11.10 Med shine
- 11.10.1 Med shine Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Med shine Herpes Labialis Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Med shine Herpes Labialis Drugs Products Offered
- 11.10.5 Med shine Recent Development
- 11.11 Bayer (Campho Phenique)
- 11.12 Blistex
- 11.13 Kelun Group
- 11.14 Hikma
- 11.15 Haiwang
- 11.16 Carmex
- 11.17 Cipher
12 Future Forecast
- 12.1 Herpes Labialis Drugs Market Forecast by Regions
- 12.1.1 Global Herpes Labialis Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Herpes Labialis Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Herpes Labialis Drugs Market Forecast by Product
- 12.2.1 Global Herpes Labialis Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Herpes Labialis Drugs Revenue Forecast by Product 2019-2025
- 12.3 Herpes Labialis Drugs Market Forecast by End User
- 12.4 North America Herpes Labialis Drugs Forecast
- 12.5 Europe Herpes Labialis Drugs Forecast
- 12.6 Asia Pacific Herpes Labialis Drugs Forecast
- 12.7 Central & South America Herpes Labialis Drugs Forecast
- 12.8 Middle East and Africa Herpes Labialis Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Herpes Labialis Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Herpes Labialis Drugs . Industry analysis & Market Report on Herpes Labialis Drugs is a syndicated market report, published as Global Herpes Labialis Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Herpes Labialis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
